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Abstract
          Clinical trials for development of new medications are essen-
tial in all fields of medicine.  The requirement for a placebo arm in 
pharmaceutical trials presents ethical and clinical dilemmas that are 
especially complicated with regard to mentally ill persons whose 
free choice and ability to provide informed consent may be ques-
tionable.  On the other hand, we do not believe that this predica-
ment justifies unconditional rejection of placebo use in psychiatry, 
when the investigational drug may ultimately provide substantial 
benefit for some patients.  At the same time it is the psychiatrist’s 
responsibility to insure that investigators are adequately trained to 
conduct clinical trials and that stringent regulatory committees su-
pervise the scientific, clinical and ethical aspects of the trials.
Keywords:  Placebo-control; Schizophrenia; Medical ethics; Clini-
cal trials
Introduction
  Clinical trials involving human subjects give rise to eth-
ical and medico-legal dilemmas. Essential research of new 
drugs may potentially expose patients to ineffective medica-
tions or to placebo.  The complexity of the issue increases 
when dealing with mentally ill patients for whom there is no 
known cure, and whose ability to provide informed consent 
to participate in clinical trials may be questionable. 
 In the absence of a consensus regarding criteria for 
placebo use Kotler and Witztum [1] claim that we are wit-
nessing a growing controversy.  This debate has practical im-
plications for Ethics Committees (Internal Review Boards) 
when deliberating approval of participation in extensive es-
sential psychopharmacological research.  The issue has been 
addressed by psychiatrists in various countries [2]. We pres-
ent the ethical considerations to be dealt with by the treating 
physicians and investigators. 
Declaration of Helsinki
   The basic principle of the Declaration is that each and 
every patient is entitled to the best treatment available [3].   
In 1996 it was determined that in all medical research, every 
patient, including those in control groups is entitled to the 
best available treatment, and that placebo may be used only 
in the event that there is no proven treatment available. 
 In the year 2000 a correction  was  added, which de-
termined that the benefits, risks and effectiveness of new 
treatments must be weighed in comparison to the very best 
available treatment, and the use of a placebo arm should be 
limited to situations where there is no proven effective treat-
ment.  
  In 2002 the World Medical Association (WMA) insert-
ed a clarification that claimed that placebo-controlled trials 
could be ethical, even where proven treatments are available 
in the event that:  there are scientific/methodological grounds 
for inclusion of placebo in the trial as an essential condition 
to prove efficacy of the drug [4].  
Research versus treatment
  Medical  treatment  and  medical  research  differ.  The 
Physician’s Oath, adopted by the General Assembly of the 
World Medical Association, (1948, amended 1968) pledges 
that “The health of my patient will be my first consideration”.   
Naturalistic or case control study designs do not interfere 
with the patients’ treatment regimens, and they are in accord 
with these principles of treatment. However investigations 
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of new drugs are randomized controlled trials which require 
research methods that often contradict accepted standards of 
treatment. 
  Determination of dosage is in accordance with the re-
search protocol, and may be influenced by additional agents 
including  investigators,  medical  institutions,  commercial 
and insurance companies [5].  
  An additional problem is that clinical trials often re-
quire a washout period during which the patient receives no 
effective treatment. 
Types of studies
  A number of study designs can be used to prove treat-
ment efficacy:  placebo-controlled trials; active-drug com-
parison trials, control group in comparison of dosages, his-
torical control groups and control groups with no treatment 
[6].  The latter two designs are not considered valid for psy-
chopharmacological studies. 
  In placebo-controlled studies, or dosage comparisons, 
the goal is to emphasize superiority of the new drug, in any 
dosage, in comparison to placebo, or a lower dosage of the 
same drug.  
  In a trial with a control group receiving active treatment 
– the aim is to prove superiority of the new drug over the ac-
tive comparator.  It is difficult to expect a new treatment to be 
better than a recognized standard therapy during the various 
stages of the study, therefore many investigators would pre-
fer the situation where studies that plan to show equal value 
or non-inferiority would be considered valid.  
  The research hypothesis that it is possible to differen-
tiate between various treatments is called assay-sensitivity.   
This assumption is based on prior studies with active stan-
dard treatments, but it should be noted that the instruments 
used for measurement in psychiatry are often based on ob-
servation, self-report or interview and not on objective mea-
sures.  Some medications that are in use and considered ef-
fective, have not always been proven as such in comparison 
to placebo. Thus, if we compare a new drug to these agents, 
we cannot scientifically prove that the new drug is effective, 
even if the trial reveals that it is of equal value to existing 
medications.  
  A placebo arm in a clinical trial enables investigation 
of assay sensitivity.  When there is no placebo arm in a trial, 
it may be necessary to increase the size of the study group 
to prove the postulation of non-inferiority, thus complicating 
performance of the study.  In addition, in such a case more 
patients will be exposed to an experimental drug whose ef-
ficacy has yet to be proven.  Similarly, the smaller the gap, 
when comparing new and existing treatments, the larger the 
study sample needed in order for the difference to have sta-
tistical significance.  
  An additional experimental possibility which is used, 
for example in cardiology, is an add-on trial drug with a 
placebo-control [7].  This method (placebo-controlled add-
on) reduces the dilemma of administering placebo, since all 
participants receive active treatment. 
Informed Consent
 Due to the potential discordance between research and 
treatment, the patient must be aware that he/she is being 
treated in the framework of a research protocol and he/she 
must provide written informed consent.  Since the compe-
tency of schizophrenia patients to provide valid informed 
consent is questionable, stringent regulation is essential for 
the informed consent process involving this population. 
 Thought disturbances and cognitive impairments char-
acteristic of schizophrenia may give rise to concern regard-
ing the ability of the patient to provide informed consent [8] 
especially patients with chronic illness [9].  
  In addition, the psychiatric patient who is hospitalized 
for long periods of time may more readily agree to partici-
pate in clinical trials offered by his attending physician, be-
cause of his/her dependency on the hospital.
  The Working Party on Research on the Mentally Inca-
pacitated, London, discussed the issue [10] and determined 
that many people with mental impairment or disorders are 
able to consent to their inclusion in research provided care is 
taken to explain it to them.  Patient’s competence should be 
evaluated using questionnaires designed especially for that 
purpose [11]. However, there are those who believe that pro-
vision of informed consent neither protects the patient nor 
ensures an ethical basis for the study since the patient’s con-
dition interferes with his/her ability to objectively weigh the 
various treatment options [12]. 
Placebo controlled trials in schizophrenia
  The need for new pharmacological treatments is based 
on the fact that some patients respond to currently avail-
able  antipsychotic  agents  with  only  partial  improvement, 
especially in all aspects related to negative schizophrenia 
symptoms. The existing treatment for this disease is effec-
tive mainly for positive symptoms and in delaying relapse 
of the disease in chronic patients.  Moreover, the efficacy of 
antipsychotics in preserving cognitive functions has yet to 
be proven.  In addition, the existing drugs, including second 
generation  medications,  have  significant  side-effects  that 
may impair the health and quality of life of schizophrenia 
patients.  In the formal sense there is no Gold Standard of 
care for negative symptoms, so it is necessary to engage in 
research that compares efficacy of the preparation to placebo 
[13].  
  In the United States, to gain Food and Drug Adminis-
tration (FDA) approval, significant proof of the efficacy of 
the drug based on adequate controlled trials must be present-
ed [14].  The majority of investigative new drug applications 
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is based on the results of placebo-controlled trials [15].  The 
European authority parallel to the FDA approves drugs based 
on trials where the new preparation is compared to placebo 
and/or treatment with standard medication. 
  Positive response to placebo in schizophrenia has been 
shown to range from 3 to 26% in various studies [16].  Dif-
ferent patients respond differently to placebo, including those 
who apparently respond better to placebo, and it is probably 
not worthwhile to include those patients, if it is possible to 
identify them ahead of time [17]. 
Difficulties  regarding  placebo  control  in 
schizophrenia and possible solutions
  The main argument against placebo use is associated 
with the inherent difficulty of the physician to refrain from 
giving the patient effective treatment.   This issue is difficult 
for  every  physician/investigator  and  especially  for  physi-
cians who treat the mentally ill.  
   Absence of active treatment may cause long and short-
term risk or harm.  Early diagnosis and treatment has been 
shown to achieve the best possible results in reducing nega-
tive symptoms [18] or improving the chance for a longer re-
mission [19].  Although some studies showed that even if the 
patients suffered exacerbation of illness after stopping active 
treatment, they returned to their basic state within a number 
of days or weeks with no long-term harm [20],  however not 
all patients enter remission following episodes of exacerba-
tion. 
  Thus, we believe that first episode patients should not 
be recruited to clinical drug trials unless the study focuses on 
treatment specific to this population. 
The emotional state of the patients and the possibility of 
cognitive impairment raise questions regarding their capac-
ity to provide informed consent for participation in research. 
  This can be avoided by routinely using questionnaires 
that specifically examine the patient’s competency to par-
ticipate in clinical trials [11].  In order to eliminate staff in-
fluence, the research staff should be distinguished from the 
caregiving staff, and an external physician may participate in 
the recruitment stages of the investigation.
 Patients receiving involuntary treatment either in the 
hospital or in the community require special consideration 
regarding recruitment to placebo-controlled trials. It is ques-
tionable whether a patient who does not consent to hospital-
ization can voluntarily consent to participation in a pharma-
ceutical trial. Alternatively, there is the view that though a 
patient may oppose treatment and hospitalization, if medi-
cation is compulsory, he/she may prefer one treatment over 
another, or may agree to a specific treatment [2]. The authors 
believe that these patients should not be included in clinical 
trials, due to the sensitivity of the issue. 
 Other opinions suggest that patients recruited to pla-
cebo studies are not necessarily representative of the general 
patient population.  They may be older, with a longer dura-
tion of illness and more willing to participate in clinical trials 
because a cure has not yet been found for their illness.  In 
addition, Placebo-controlled trials have a higher dropout rate 
[21].
  A significant problem in commercial studies is the fi-
nancial aspect: Today, most clinical trials for new drug ap-
plications  are  designed  and  sponsored  by  pharmaceutical 
companies.  Commercial companies are interested in place-
bo-controlled trials and the direct financial relationship be-
tween the company and the investigator may be problematic 
[22], and should be avoided.  
  The investigator must assure beneficence, a favorable 
balance between the potential benefit and harm of participa-
tion. 
Discussion
 There is no known pharmacological cure for schizo-
phrenia. Treatment provided by physicians is in accord with 
the current knowledge of the illness, and is dispensed to al-
leviate the symptoms and to improve the patient’s ability to 
function, and quality of life. Physicians will always hesitate 
to expose a patient to an unfamiliar agent when a known 
medication is obtainable. On the other hand, without medi-
cal research and clinical trials, we would not have the effec-
tive medications that we have today, which pending ongoing 
medical research, may indeed be replaced by more effective 
preparations in the future. 
 The increasing rift surrounding the use of placebo in 
trials for the development of new psychiatric medications, 
involves scientific, clinical and ethical issues.  It seems that 
there is no single all encompassing approach either for or 
against placebo-controlled trials.   Placebo use is problem-
atic in medicine. Administering treatment which in fact may 
be a placebo alters the physician-patient relationship, espe-
cially when dealing with mental health patients suffering 
from schizophrenia.  However, since there is no known cure 
for the disease, research is essential in this population, so it 
may be justifiable to encourage patient participation in clini-
cal trials to advance medical knowledge in the field. In most 
cases the use of an active control in schizophrenia research is 
ethically and scientifically preferable [23]. This is not always 
possible. 
  It is the investigator’s responsibility to ensure that clini-
cal trials are designed and conducted according to appropri-
ate clinical and ethical principles and that each proposed 
trial is based on solid hypothesis according to which the new 
treatment will be more effective and/or have less side-effects 
than existing treatment. 
  In a clinically justified trial, when including a placebo 
control group, the size of the placebo group and duration of 
administration of placebo should be as limited as possible 
and the duration of the medication washout period should be 
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as short as possible. 
  A balanced approach should allow for placebo use 
while examining the various aspects and delineating safe-
guarding  restrictions  accordingly  [24].  The  investigator 
should bear in mind that referring a patient to participate in 
a study is basically positive. 
  It should be emphasized  that participation in clinical 
studies has benefits for the patient,  such as increased moni-
toring and clinical care in the research setting where he/she 
is examined more frequently, intensified psycho-social ser-
vices, and the opportunity to continue to receive the experi-
mental drug free of charge following successful completion 
of the study. 
  Active quality control of clinical trials should be car-
ried out by the trial sponsor or by their representatives [25].   
Quality control begins from the stage of the presentation of 
the study protocol to the potential investigator for a feasibil-
ity review, and is complete when conclusions are drawn and 
findings are reported.  
    It  is  important  to  train  young  investigators  in  the 
methodology and guidelines for good clinical practice for 
management of clinical trials, with emphasis on the special 
issues involving psychiatric patients.   Conducting trials in 
accordance with the International Conference of Harmoniza-
tion (ICH/GCP) Harmonized Tripartite Guidelines for Good 
Clinical Practice [26] provides assurance of quality research 
and patient protection. In addition, Internal Review Boards 
and ethics committees are responsible for safeguarding the 
rights, safety and well-being of all trial subjects, with special 
attention to trials that may include vulnerable subjects.  
Conclusions
  Clinical pharmaceutical trials are essential for the de-
velopment of new medications in all fields of medicine, in-
cluding psychiatry.  The requirement for a placebo arm in 
pharmaceutical trials presents ethical and clinical dilemmas 
that are especially complicated with regard to mentally ill 
persons whose free choice and ability to provide informed 
consent may be questionable. The authors do not believe that 
this predicament justifies unconditional rejection of placebo 
use in psychiatry. Each case should be considered and evalu-
ated for risks and benefits for participants and for the general 
patient population involved. 
 It is therefore important to require adequate training 
and certification for investigators and to provide stringent 
restrictions that will enable strict supervision over the scien-
tific, clinical and ethical aspects of clinical trials.
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